Uncovering Biologically Coherent Peripheral Signatures of Health and Risk for Alzheimer’s Disease in the Aging Brain
暂无分享,去创建一个
Paul M. Thompson | Aram Galstyan | Greg Ver Steeg | Madelaine Daianu | Adam Mezher | Lauren E. Salminen | P. Thompson | A. Galstyan | Brandalyn C. Riedel | Madelaine Daianu | A. Mezher | Greg Ver Steeg | P. Thompson | P. Thompson
[1] Kaj Blennow,et al. Biomarkers in Alzheimer's disease drug development , 2010, Nature Medicine.
[2] Ralph A. Nixon,et al. Autophagy failure in Alzheimer's disease—locating the primary defect , 2011, Neurobiology of Disease.
[3] Keith A. Johnson,et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.
[4] Alex Bateman,et al. The rise and fall of supervised machine learning techniques , 2011, Bioinform..
[5] Derick R. Peterson,et al. Plasma phospholipids identify antecedent memory impairment in older adults , 2014, Nature Medicine.
[6] G. Wagner,et al. Structural alterations in patients with obsessive–compulsive disorder: a surface-based analysis of cortical volume, surface area and thickness , 2017, Journal of psychiatry & neuroscience : JPN.
[7] Walter J Koroshetz,et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. , 2012, Archives of neurology.
[8] M. Kamal,et al. Inflammatory Process in Alzheimer's and Parkinson's Diseases: Central Role of Cytokines. , 2016, Current pharmaceutical design.
[9] A. Fleisher,et al. The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers. , 2014, The Journal of clinical psychiatry.
[10] J. Friedman. Greedy function approximation: A gradient boosting machine. , 2001 .
[11] J. Morris,et al. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials , 2017, Alzheimer's & Dementia.
[12] Wendy R. Sanhai,et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.
[13] C. Jack,et al. Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2010, Neurology.
[14] Nick C Fox,et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.
[15] B. Winblad,et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease , 2010, Neurology.
[16] Isabelle Guyon,et al. An Introduction to Variable and Feature Selection , 2003, J. Mach. Learn. Res..
[17] R. Brookmeyer,et al. National estimates of the prevalence of Alzheimer’s disease in the United States , 2011, Alzheimer's & Dementia.
[18] Stephen M. Rao,et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.
[19] Shirley Pepke,et al. Comprehensive discovery of subsample gene expression components by information explanation: therapeutic implications in cancer , 2016, BMC Medical Genomics.
[20] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[21] Guangji Wang,et al. Thinking outside the brain for cognitive improvement: Is peripheral immunomodulation on the way? , 2015, Neuropharmacology.
[22] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[23] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[24] Philip S. Insel,et al. Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2012, Brain Imaging and Behavior.
[25] Y. Qian,et al. Enhanced production of amyloid precursor protein mRNA by peripheral mononuclear blood cell in Alzheimer's disease , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[26] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[27] Yu-ping Peng,et al. Th17 Cell-Mediated Neuroinflammation Is Involved in Neurodegeneration of Aβ1-42-Induced Alzheimer’s Disease Model Rats , 2013, PloS one.
[28] P. Mcgeer,et al. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease , 2000, Brain Research.
[29] R. Sperling,et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. , 2014, JAMA neurology.
[30] W. Poon,et al. Tau Spread, Apolipoprotein E, Inflammation, and More: Rapidly Evolving Basic Science in Alzheimer Disease. , 2017, Neurologic clinics.
[31] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.
[32] Simon Lovestone,et al. Alzheimer's disease – do tauists and baptists finally shake hands? , 2002, Trends in Neurosciences.
[33] Michael Weiner,et al. Unbiased tensor-based morphometry: Improved robustness and sample size estimates for Alzheimer's disease clinical trials , 2013, NeuroImage.
[34] Yoram Singer,et al. Using and combining predictors that specialize , 1997, STOC '97.
[35] L. Tan,et al. Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. , 2015, Annals of translational medicine.
[36] Jakub Szlęk,et al. Empirical modeling of the fine particle fraction for carrier-based pulmonary delivery formulations , 2015, International journal of nanomedicine.
[37] D. Catalucci,et al. Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin , 2015, Nature Medicine.
[38] L. Launer,et al. Midlife C-reactive protein and risk of cognitive decline: A 31-year follow-up , 2009, Neurobiology of Aging.
[39] Alzheimer’s Association. 2018 Alzheimer's disease facts and figures , 2018, Alzheimer's & Dementia.
[40] T. Rutherford,et al. Serum amyloid A , 2010, Cancer.
[41] D. Frayer. SEXUAL DIMORPHISM , 2005 .
[42] Justin Bedo,et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. , 2012, Archives of neurology.
[43] G. Getz,et al. The mutual interplay of lipid metabolism and the cells of the immune system in relation to atherosclerosis , 2014, Clinical lipidology.
[44] P. Kubes,et al. The neutrophil in vascular inflammation , 2011, Nature Medicine.
[45] Verónica Bolón-Canedo,et al. Ensemble feature selection: Homogeneous and heterogeneous approaches , 2017, Knowl. Based Syst..
[46] Aram Galstyan,et al. Maximally Informative Hierarchical Representations of High-Dimensional Data , 2014, AISTATS.
[47] I. T. Ten Berge,et al. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. , 1996, Journal of immunology.
[48] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[49] K. Jellinger,et al. Synaptic Pathology of Alzheimer's Disease a , 1993, Annals of the New York Academy of Sciences.
[50] A. Batra,et al. Altered lymphocyte distribution in Alzheimer's disease. , 2007, Journal of psychiatric research.
[51] Paul M. Thompson,et al. Age, APOE and sex: Triad of risk of Alzheimer’s disease , 2016, The Journal of Steroid Biochemistry and Molecular Biology.
[52] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[53] J. Hardy,et al. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.
[54] M. Naito,et al. Increased Susceptibility of Thymocytes to Apoptosis in Mice Lacking AIM, a Novel Murine Macrophage-derived Soluble Factor Belonging to the Scavenger Receptor Cysteine-rich Domain Superfamily , 1999, The Journal of experimental medicine.
[55] Eric Westman,et al. Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion , 2012, NeuroImage.
[56] Gonzalo A. Bello,et al. Toward Personalized Network Biomarkers in Alzheimer's Disease: Computing Individualized Genomic and Protein Crosstalk Maps , 2017, Front. Aging Neurosci..
[57] Nathan D. Price,et al. IL-10 Alters Immunoproteostasis in APP Mice, Increasing Plaque Burden and Worsening Cognitive Behavior , 2015, Neuron.
[58] Greg Ver Steeg,et al. Unsupervised Learning via Total Correlation Explanation , 2017, IJCAI.
[59] C. Visser,et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. , 1997, Circulation.
[60] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[61] Michael Weiner,et al. Maximizing power to track Alzheimer's disease and MCI progression by LDA-based weighting of longitudinal ventricular surface features , 2013, NeuroImage.
[62] H. Vankova. Mini Mental State , 2010 .
[63] P. Tariot,et al. Establishing Composite Cognitive Endpoints for Use in Preclinical Alzheimer's Disease Trials. , 2015, The journal of prevention of Alzheimer's disease.
[64] A. Hofman,et al. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. , 2004, Archives of neurology.
[65] J. Morris,et al. The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement , 2017, Alzheimer's & Dementia.
[66] I. Melle,et al. Cortical Volume, Surface Area, and Thickness in Schizophrenia and Bipolar Disorder , 2012, Biological Psychiatry.
[67] R. Tibshirani,et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.
[68] P. Kubes,et al. Neutrophil recruitment and function in health and inflammation , 2013, Nature Reviews Immunology.
[69] W. Koenig,et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[70] David A. Bell,et al. A Formalism for Relevance and Its Application in Feature Subset Selection , 2000, Machine Learning.
[71] L. Westlye,et al. Differential Longitudinal Changes in Cortical Thickness, Surface Area and Volume across the Adult Life Span: Regions of Accelerating and Decelerating Change , 2014, The Journal of Neuroscience.
[72] A. Whitehead,et al. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. , 1994, Immunology today.
[73] Reisa A. Sperling,et al. Preclinical Alzheimer’s Disease , 2014 .
[74] Norbert Schuff,et al. Accurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry , 2011, NeuroImage.
[75] Lennart Thurfjell,et al. Blood protein predictors of brain amyloid for enrichment in clinical trials? , 2015, Alzheimer's & dementia.
[76] Rena Li,et al. Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes , 2006, Neurobiology of Aging.
[77] P. Mcgeer,et al. The pentraxins: possible role in Alzheimer’s disease and other innate inflammatory diseases , 2001, Neurobiology of Aging.
[78] David A. Bennett,et al. Sexual dimorphism in predisposition to Alzheimer's disease , 2018, Neurobiology of Aging.
[79] Aram Galstyan,et al. Discovering Structure in High-Dimensional Data Through Correlation Explanation , 2014, NIPS.
[80] Kathryn Ziegler-Graham,et al. Forecasting the global burden of Alzheimer’s disease , 2007, Alzheimer's & Dementia.
[81] R. Mohs,et al. The Alzheimer's Disease Assessment Scale , 1996, International Psychogeriatrics.
[82] C. P. Hughes,et al. A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.
[83] F. Borràs,et al. The human CD5L/AIM-CD36 axis: A novel autophagy inducer in macrophages that modulates inflammatory responses , 2015, Autophagy.
[84] Gretel Sanabria-Diaz,et al. Surface area and cortical thickness descriptors reveal different attributes of the structural human brain networks , 2010, NeuroImage.
[85] S. Scheff,et al. Synaptic pathology in Alzheimer’s disease: a review of ultrastructural studies , 2003, Neurobiology of Aging.
[86] E. Reiman,et al. Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.
[87] C. Mold,et al. Serum amyloid P component binds to histones and activates the classical complement pathway. , 1992, Journal of immunology.